Open Access

Welcome and introduction - The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy.

Topic: Thrombosis and platelets
Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

Congress Session

About the speaker

Professor Davide Capodanno

University of Catania, Catania (Italy)
24 presentations
4 followers

7 more presentations in this session

The patient journey after an acute coronary syndrome - A clinical case study.

Speaker: Professor S. James (Uppsala, SE)

Thumbnail

Discussion - The patient journey after an acute coronary syndrome - A clinical case study.

Speaker: Professor D. Capodanno (Catania, IT) Professor C. Hamm (Bad Nauheim, DE) Professor S. James (Uppsala, SE) Doctor M. Bonaca (Aurora, US) Professor P. Steg (Paris, FR)

Thumbnail

Optimising antiplatelet therapy from first medical contact to discharge.

Speaker: Professor P. Steg (Paris, FR)

Thumbnail

Discussion - Optimising antiplatelet therapy from first medical contact to discharge.

Speaker: Professor D. Capodanno (Catania, IT) Professor C. Hamm (Bad Nauheim, DE) Professor S. James (Uppsala, SE) Doctor M. Bonaca (Aurora, US) Professor P. Steg (Paris, FR)

Thumbnail

Who, when and why - The rationale to treat beyond 12 months.

Speaker: Doctor M. Bonaca (Aurora, US)

Thumbnail

Access the full session

The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy

Speakers: Professor D. Capodanno, Professor S. James, Professor D. Capodanno, Professor C. Hamm, Professor S. James...
Thumbnail

About the event

Image

ESC CONGRESS 2016

27 August - 31 August 2016

Sessions Presentations

Related content

Open Access

MASTER DAPT - Discussant review.

28 August 2021

Open Access

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - panel .

27 August 2021

Open Access

Classification of HF and diagnosis and treatment of HFmrEF and HFpEF.

27 August 2021

This platform is supported by

logo Novo Nordisk